Neuralstem (Symbol CUR) Kaufempfehlung 0,98 US$ Kursziel in 2012 3,00 - 500 Beiträge pro Seite

[kfz]

Homepage http://www.neuralstem.com/ Die Gesellschaft ist hochinteressant und ist auf dem Gebiet neuronale Stammcellenforschung Nr. 1 in der Welt !!!
Wer sich in diesem Bereich einliest und die Gesellschaft analysiert wird viel Freude im Jahre 2012 haben. Die Aktie ist auf einem 5-jahrestief--- erstes Kursziel 3,00 US$, aber Kurse von 20-30 US$ bei Übernahme der Gesellschaft durchaus denkbar. Die Gesellschaft ist im focus der amerikanischen Medien wie Fox oder CNN usw. Nochmals unbedingt Hompage anschauen.

Ps. Stammcellenforschung ist in Deutschland verboten, aber es ist um so interessanter welche Erfolge die Gesellschaft gegen ALS erzielt !!!!

gelistet AMEX Symbol CUR und Frankfurt Marketcap 48 mio US§

PS: Ich beobachte die Gesellschaft seit 2 Jahren !!!

[Datteljongleur]

Antwort auf Beitrag Nr.: 42.513.976 von kfz am 22.12.11 14:21:44

PS: Ich beobachte die Gesellschaft seit 2 Jahren !!!

Und, auch investiert seit 2 Jahren?

[kfz]

heute war CUR schon bei 0,91, aber m.E. gute Einstiegskurse !!! Wer die Homepage liest wird ebenfalls festellen, dass man mit der Uni Freiburg zusammenarbeitet. Wenn das sogenannte "Tax-selling" in den USA am Jahresende beendet ist, wird die Aktie wieder in Richtung norden gehen. Man braucht aber gute Nerven um hier zu investieren!!!

[kfz]

http://finance.yahoo.com/q/bc?s=CUR&t=5y&l=on&z=l&q=l&c=

Diesen Chart einfach anschauen und einwirken lassen !!!!

[Bunte17]

Antwort auf Beitrag Nr.: 42.517.171 von kfz am 23.12.11 10:31:19

Sieht nach 0,5 aus im Juni

[kfz]

Aber nicht mit solchen News wie heute veröffentlicht wurde!!!!

Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
First Neuroregenerative Compound Tested In Depression







ROCKVILLE, Md., Dec. 27, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD as well as other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"We are pleased to be approved to begin testing NSI-189 in patients who suffer from depression," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "Loss of hippocampal volume is a known characteristic in depressed patients. NSI-189 stimulates neurogenesis and increases hippocampal volume in healthy adult mice, at the same time reversing behavioral symptoms in mouse depression models, so it could address depression at the source."

"It is exciting to see a new class of drugs that potentially offers a novel and different approach to this disease moving into patients," said Maurizio Fava, MD, Slater Family Professor of Psychiatry at Harvard Medical School and Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital. Dr. Fava, one of the world's leading researchers in MDD, helped design the Neuralstem trial.

[kfz]

Heute ist der letzte Tag für das sogenanntes "Tax-selling"!!!!

[kfz]

technische Analyse für Neuralstem (CUR) Amex vom

Technical Analysis
as of: 2012-01-03 5:25:30 PM


Overall


Our rating system posted a STRONG BUY today, upgraded from lower rating. The market seems to be very strong for long buyers. If you bought, continue to hold stock until SELL signal. You are relatively safe as long as the SELL warning is not issued.

Target
Six months: 1.37 One year: 1.60

Support
Support1: 0.86 Support2: 0.72

Resistance
Resistance1: 1.18 Resistance2: 1.37

Pivot
0.99

Moving Averages
MA(5): 0.95 MA(20): 0.99

MA(100): 1.21 MA(250): 1.48

MACD
MACD(12,26): -0.05 Signal(12,26,9): -0.05

Stochastic Oscillator
%K(14,3): 49.12 %D(3): 40.02

RSI
RSI(14): 46.36

52-Week
High: 2.35 Low: 0.86 Change(%): -53.1

Average Volume(K)
3-Month: 75 10-Days 117

[kfz]

http://gizmodo.com/5874433/the-pill-that-could-cure-depressi…

Ein sehr guter Artikel über Neuralstem

[kfz]

..Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase

Press Release: Neuralstem, Inc. – 13 hours ago
....
Share0EmailPrint.....Companies:...Neuralstem, Inc. . ...RELATED QUOTES.
.Symbol Price Change
CUR 0.9908 0.00

......



ROCKVILLE, Md. , Jan. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10 , 1:45-3:00pm PT . Garr will serve on the Therapeutic Focus Panel entitled, "Neurodegenerative Disease, Ophthalmology and Spinal Injury," featured in the Alliance for Regenerative Medicine (ARM) Insight Track. Garr will also present a business overview, including an update on the world's first FDA-approved stem cell injections in the cervical region, in its ongoing ALS cell therapy Phase I trial. He will also present an update on the recently FDA-approved advancement to Phase Ib dosing in depressed patients of its first-in-class NSI-189 small molecule drug, in its ongoing NSI-189/major depressive disorder (MDD) trial.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San Francisco , January 9-11 . For more information, see: http://www.ebdgroup.com/bts/index.php. Biotech Showcase runs concurrently to the world's largest annual healthcare investor conference, and provides private and public life science companies the opportunity to present to an audience of investors and business development executives interested in innovative biotech companies.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington 's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

[kfz]

Dabei bleiben heute schon ca. 7 % höher!!! Erst der Anfang!!!

[kfz]

vielleicht schließt die Aktie über 1,10 wäre gut!!

[kfz]

Die Firma Neuralstem :

Business Summary

Neuralstem, Inc., a biopharmaceuticals company, focuses on the development and commercialization of treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. It uses its proprietary human neural stem cell technology as a tool for use in the small-molecule drug discovery, as well as to create cell therapy biotherapeutics for the treatment of central nervous system diseases, various neurodegenerative conditions, and for the regenerative repair of acute diseases. The company was founded in 1996 and is headquartered in Rockville, Maryland.

[kfz]

lest den nachfolgenden Artikel, dann wisst Ihr warum die Aktie steigen wird !!!!

The Pill That Could Cure Depression by Growing Your Brain
If you are depressed, or schizophrenic or have Alzheimer's, scientists say you probably have a shrunken hippocampus. The good news: a drug that just entered human trials promises to re-grow that part of the brain.

It's an entirely new approach to treating clinical depression, which is the first of several diseases scientists at biotech company Neuralstem are hoping to address with their experimental oral drug. Most antidepressants work on brain chemistry, tweaking levels of neurotransmitters including serotonin, norepinephrine, and dopamine. This is the first drug that aims to re-grow patients' atrophied brains.

Dr. Karl Johe, Neuralstem's CEO, believes that depression is a three-headed beast that affects neurotransmitter levels, neurons, and hippocampus size. And he says their new drug could address all three. He also hopes the drug will reverse the disease to the point that patients could permanently go off the drug.

"If we can show by MRI that we've increased hippocampus volume and at the same time reversed depression symptoms for six months after patients have stopped taking the drug, then we'll have a cure."

That a too-small hippocampus causes depression and other diseases is still technically a theory in humans (though it's been demonstrated in rats and chimps). So if the drug grows hippocampus volume and thereby treats depression, we'll not only have a new treatment, but the study results would be proof that a shriveled hippocampus is at least in part the culprit.

The scientists showed first that the drug worked in the lab: They started with dishes of neural stem cells and added several compounds they thought might instigate growth. Seven showed promise, but they could only afford to develop one, so they chose NSI-189. They then tested it in mice; after taking the drug, the rodents had larger hippocampi.

Thirty-five healthy humans have now taken the drug with no ill effects, so the FDA gave the company the OK to start testing in depressed patients. They'll give the pill to 18 volunteers (six will get a placebo) in three groups, each receiving a progressively larger dose, each over 28 days. They expect this phase, which is mainly to make sure the drugs is safe, to take about six months. If all goes well they hope to proceed to phase two clinical trials later this year, which will test to determine whether the drug is both safe and effective. (After that, a final phase three trial to confirm safety and efficacy will remain before the company can market the drug.)

I couldn't help thinking about those healthy test subjects who took the drug. Will they get super brain powers? The healthy mice that received the drug did grow extra large hippocampi, the seahorse-shaped part of the brain involved with both short and longterm memory and spatial navigation. Johe isn't ruling out the possibility of souped-up brains:

"It's an exciting possibility and we'll definitely be looking out for it."

Image: Shutterstock/Andrii Muzyka

[kfz]

plus 25 % plus 25% plus 25 % heute es klingelt die Kasse

dabei bleiben, dabei bleiben


bitte keinen Dank !!!!!!

[kfz]

plus 25 % plus 25% plus 25 % heute es klingelt die Kasse

dabei bleiben, dabei bleiben


bitte keinen Dank !!!!!!

[kfz]

Die Ruhe vor dem Sturm ""

[kfz]

dabei sein und dabei bleiben ist alles !!!! Der Weg ist das Ziel!!!!

[kfz]

CUR ist am 13.2.2012 auf einer sehr bedeutenden Investoren Konferenz
siehe News today, könnte mir vorstellen größere Kurssteigerungen in den nächsten Wochen !?

[kfz]

wir sind vor dem Ausbruch in Richtung 1,30 bis 1,40 US, dabei bleiben ist alles !!!

[kfz]

ROCKVILLE, Md., Feb. 8, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 14th Annual BIO CEO & Investor Conference 2012 in New York City on Monday, February 13, at 3:00 p.m. EST. Garr will present a business overview, and an update on the company's ongoing clinical trials in both its cell therapy and pharmaceutical divisions.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The webcast will be available in real-time at http://www.veracast.com/webcasts/bio/ceoinvestor2012/4311424… and again beginning one hour after the conclusion of the live event, and archived for 90 days. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.

The BIO CEO & Investor Conference 2012 will be held at the Waldorf=Astoria in New York City, February 13-14. For more information, see: http://www.bio.org/events/conferences/14th-annual-bio-ceo-in… Now in its 14th year, the BIO CEO & Investor Conference is billed as the largest independent investor conference focused on publicly traded biotechnology companies.

Neuralstem's President and CEO Richard Garr is also scheduled to present at the 6th Annual BIO-Europe Spring Conference 2012, March 19-21, in Amsterdam, Holland. Please see http://www.ebdgroup.com/bes/index.php for more information.

[kfz]

heute start mit 1,30 + 7,5% wer jetzt die Gesellschaft nicht analysiert hat ist selbst schuld wenn er eine Chance verpasst !!!

[kfz]

Neuralstem, Inc.
Rating: Buy
Capital Raised - Looking Ahead To 2012 Catalysts
Investment Highlights:
n Existing Investors Pony Up Capital. Last week, Neuralstem raised
$5.2mm in gross proceeds from select existing institutional investors
in an equity financing transaction. We believe that the firm now has
adequate capital reserves to finance its operations through the remainder
of this year. 2012 promises to be an important period for Neuralstem, as
the company continues to progress with its stem cell-based therapeutic
approach for treatment of amyotrophic lateral sclerosis (ALS) or Lou
Gehrig's disease and expects to complete initial clinical testing of its lead
small molecule therapeutic agent, NSI-189, by the summer of 2012. In
the wake of the most recent financing transaction and in anticipation of
several important near-term catalysts, we reiterate our Buy rating and 12-
month price target of $5.00 on Neuralstem shares.
n ALS Trial Continues To Progress. We note that Neuralstem's Phase
1 ALS trial of the firm's proprietary neural stem cell-based therapeutic
continues to fare well, with no safety concerns emerging thus far. The
company expects to complete the final administrations of the stem cells
to the subjects enrolled in the final cohort of the trial by late June 2012,
and lock the database at the end of the year. Interim data could be
presented early next year, potentially at the next meeting of the American
Neurological Association (ANA) in April 2013. Should there be signs of
efficacy, we expect Neuralstem to file for permission from the U.S. FDA
to begin pivotal development of the therapy in ALS patients. A single
positive pivotal trial would likely be sufficient for approval of this product
candidate, considering the fact that ALS remains an utterly unmet medical
need and a chronic neurodegenerative condition that is invariably fatal
within a 3-5-year time frame.
n Small Molecule Program A Hidden Value Driver. Neuralstem is also
developing a neurogenic compound designated NSI-189. In our view,
this provides the firm with a bimodal drug development pipeline, which
differentiates the company substantially from other companies that are
purely stem cell plays. While NSI-189 remains an early-stage project,
we expect Neuralstem to initiate dosing in a Phase 1b trial of the drug
within the coming weeks. Complete data from this study is expected
to be available in the summer of 2012, and could lead to a territoryspecific
licensing deal or option-based transaction with an established
pharmaceutical firm late in the year.

[kfz]

gutes volumen heute und steigende Kurse, können wir vielleicht noch einiges erwarten diese Woche???

[kfz]

Es war nichts für schwache Nerven!!!! Jetzt unbedingt beobachten!!!

[kfz]

Vielleicht sehen wir einen Anstieg in Richtung 1,60$!? Heute ???

Gestriges High 1,55 !!!